Literature DB >> 21779850

Erythropoietic neuroprotection: Holy Grail or potential to fail?

Katerina Pavenski, Gregory M T Hare, C David Mazer.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21779850     DOI: 10.1007/s00134-011-2305-2

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  20 in total

Review 1.  Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.

Authors:  J Douglas Rizzo; Mark R Somerfield; Karen L Hagerty; Jerome Seidenfeld; Julia Bohlius; Charles L Bennett; David F Cella; Benjamin Djulbegovic; Matthew J Goode; Ann A Jakubowski; Mark U Rarick; David H Regan; Alan E Lichtin
Journal:  Blood       Date:  2007-10-22       Impact factor: 22.113

Review 2.  Emerging biological roles for erythropoietin in the nervous system.

Authors:  Michael Brines; Anthony Cerami
Journal:  Nat Rev Neurosci       Date:  2005-06       Impact factor: 34.870

Review 3.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  J Bohlius; J Wilson; J Seidenfeld; M Piper; G Schwarzer; J Sandercock; S Trelle; O Weingart; S Bayliss; S Brunskill; B Djulbegovic; C L Benett; S Langensiepen; C Hyde; E Engert
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

Review 4.  Erythropoietic stimulating agents.

Authors:  Ugo Testa
Journal:  Expert Opin Emerg Drugs       Date:  2010-03       Impact factor: 4.191

5.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

6.  Absence of functional EpoR expression in human tumor cell lines.

Authors:  Susan Swift; Aaron R Ellison; Paul Kassner; Ian McCaffery; John Rossi; Angus M Sinclair; C Glenn Begley; Steven Elliott
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

7.  Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells.

Authors:  Angus M Sinclair; Angela Coxon; Ian McCaffery; Stephen Kaufman; Katherine Paweletz; Liqin Liu; Leigh Busse; Susan Swift; Steven Elliott; C Glenn Begley
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

8.  Derivatives of erythropoietin that are tissue protective but not erythropoietic.

Authors:  Marcel Leist; Pietro Ghezzi; Giovanni Grasso; Roberto Bianchi; Pia Villa; Maddalena Fratelli; Costanza Savino; Marina Bianchi; Jacob Nielsen; Jens Gerwien; Pekka Kallunki; Anna Kirstine Larsen; Lone Helboe; Søren Christensen; Lars O Pedersen; Mette Nielsen; Lars Torup; Thomas Sager; Alessandra Sfacteria; Serhat Erbayraktar; Zubeyde Erbayraktar; Necati Gokmen; Osman Yilmaz; Carla Cerami-Hand; Qiao-Wen Xie; Thomas Coleman; Anthony Cerami; Michael Brines
Journal:  Science       Date:  2004-07-09       Impact factor: 47.728

9.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

10.  Efficacy and safety of epoetin alfa in critically ill patients.

Authors:  Howard L Corwin; Andrew Gettinger; Timothy C Fabian; Addison May; Ronald G Pearl; Stephen Heard; Robert An; Peter J Bowers; Paul Burton; Mark A Klausner; Michael J Corwin
Journal:  N Engl J Med       Date:  2007-09-06       Impact factor: 91.245

View more
  1 in total

1.  Year in review in Intensive Care Medicine 2011: I. Nephrology, epidemiology, nutrition and therapeutics, neurology, ethical and legal issues, experimentals.

Authors:  Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2012-01-04       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.